Azitra, Inc. announced positive results from an ex vivo study of its cosmetic product candidate, ATR-COSF, which demonstrated the ability to reduce the appearance of fine lines and improve elasticity in human skin samples. The study showed continued improvement for up to 48 hours after a single application. Following these results, the company anticipates releasing initial data from its first-in-human clinical study by the end of 2026.
Key Details
- Study Results: In one model, a single dose of ATR-COSF reduced the appearance of fine lines and wrinkles by approximately 20% at 24 hours and 50% at 48 hours, while also preserving net skin elasticity.
- Next Steps: A first-in-human clinical study of 4% ATR-COSF in approximately 30 subjects is underway, with initial data expected by the end of 2026.
- Financing Update: Effective October 26, 2026, the company will not utilize its at-the-market (ATM) offering program for the foreseeable future, citing its current capital resources and the recent stock price.